We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 21, 2021

Intraperitoneal Bevacizumab to Treat Symptomatic Ascites in Chemotherapy-Resistant, Epithelial Ovarian Cancer

Gynecologic Oncology


Additional Info

Gynecologic Oncology
REZOLVE (ANZGOG-1101): A Phase 2 Trial of Intraperitoneal Bevacizumab to Treat Symptomatic Ascites in Patients With Chemotherapy-Resistant, Epithelial Ovarian Cancer
Gynecol. Oncol 2021 Feb 23;[EPub Ahead of Print], KM Sjoquist, D Espinoza, L Mileshkin, S Ananda, C Shannon, S Yip, J Goh, D Bowtell, M Harrison, ML Friedlander

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading